special safety topics included cardiovascular risk, priapism, non-arteritic anterior ischaemic optic neuropathy (naion), impaired renal and hepatic function, drug interactions (i.e. nitrates, cytochrome p3a4 inhibitors, other ed therapies and Î±-blockers) and incorrect use.